A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another blow to research on a once-promising target.
The decision to halt the trial underscores the challenges faced in the oncology sector, particularly with combination therapies that have not met efficacy expectations. The cancellation raises questions about the viability of TIGIT as a therapeutic target, which had previously garnered significant interest from investors and researchers alike. As companies navigate the complexities of drug development, this setback may prompt a reevaluation of pipeline strategies and partnerships, particularly for firms involved in similar therapeutic areas.
For stakeholders in regulatory, QA/QC, CMC, and sourcing roles, these developments signal a need for heightened scrutiny and adaptability in project management and investment decisions, as the landscape continues to evolve amid ongoing clinical challenges.
Use the database as your supply chain compass →
